fibrin clot

Hematin (Ferrihemic acid) is an iron-containing porphyrin. It is used for testing in vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.

Bismuth subgallate (Dermatol Puder) is an astringent and antiseptic and is applied to skin diseases such as eczema.

Rivaroxaban (BAY 59-7939) is an orally bioavailable oxazolidinone derivative and a direct inhibitor of coagulation factor Xa with anticoagulant activity. Upon administration, it selectively binds to both free factor Xa and factor Xa within the prothrombinase complex, interfering with the conversion of prothrombin (factor II) to thrombin and preventing cross-linked fibrin clot formation. Rivaroxaban does not affect existing thrombin levels.

YZ-202 is the free acid form of orbofiban. As a class II GPIIb IIIa antagonist, YZ-202 has comparable efficacy to class I antagonists (such as XV459 and DMP802) in inhibiting platelet aggregation, but shows lower potential in altering TF-mediated clot formation strength. This suggests that despite similar anti-aggregation efficacy, YZ-202 may exhibit different effects on platelet-fibrin clot contraction.

AR-H067637 is a rapid-binding, reversible and potent (inhibition constant K(i) = 2-4 nM), competitive inhibitor of thrombin, as well as of thrombin bound to fibrin (clot-bound thrombin) or to thrombomodulin. The total amount of free thrombin generated in

Hirudin (54-65; non-sulfated) is a desulfated peptide fragment of hirudin, an anticoagulant produced byH. medicinalis.1It inhibits fibrin clot formation induced by isolated bovine thrombin with an IC50value of 3.7 μM.2 1.Niehrs, C., Huttner, W.B., Carvallo, D., et al.Conversion of recombinant hirudin to the natural form by in vitro tyrosine sulfation. Differential substrate specificities of leech and bovine tyrosylprotein sulfotransferasesJ. Biol. Chem.265(16)9314-9318(1990) 2.Payne, M.H., Krstenansky, J.L., Yates, M.T., et al.Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptidesJ. Med. Chem.34(3)1184-1187(1991)

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide with greater thrombin affinity than Hirugen, exhibiting a dissociation constant (K D) of less than 100 nM. This compound acts as an antithrombotic agent, effectively inhibiting thrombin-induced fibrin clot formation with an inhibitory concentration (IC 50) of 0.087 μM [1].

Bemiltenase alfa is a hemostatic agent that targets coagulation factor X (FX). It activates FX to facilitate the conversion of prothrombin into thrombin, which subsequently transforms fibrinogen into fibrin, thereby forming a stable blood clot and exerting its hemostatic effect. Bemiltenase alfa shows potential for research in bleeding symptoms associated with hemophilia.

Nonacog gamma is a coagulation factor IX (FIX) supplement that activates factor X (FX), facilitating the generation of thrombin, which then converts fibrinogen into fibrin to form a stable blood clot and exert hemostatic effects. Nonacog gamma holds potential for research in the treatment of hemophilia B.